stockrow
Friday 6 November 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
7.99
0.25
+3.23%
Follow IOVA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.60 | 5.76 | 5.14 | 3.70 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1,492.57) | (30.78) | (20.38) | (18.56) | |
P/B ratio |
8.21 | 2.54 | 2.04 | 1.40 | |
Price to Tangible BV |
12.05 | 3.97 | 3.25 | 2.33 | |
EV/Sales |
16.82 | 4.85 | 4.05 | 2.58 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(33.56) | (5.97) | (4.27) | (2.25) | |
EV/FCF |
(29.51) | (5.32) | (3.79) | (2.02) | |
Quick Ratio |
1.01 | 3.74 | 3.05 | 2.74 | |
Current Ratio |
5.20 | 4.35 | 3.60 | 3.20 | |
Net Debt/EBITDA |
— | 6.76 | 4.44 | 4.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.36 | 0.30 | 0.29 | |
Operating CF/Net income |
0.20 | 1.29 | 0.91 | 0.73 | |
Capex/Depreciation |
0.00 | (0.69) | (0.63) | (0.82) | |
Research and Development Expense of Revenue |
0.00% | 59.26% | 87.48% | 82.06% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 39.54% | 54.53% | 41.95% | |
Intangible Assets out of Total Assets |
0.26 | 0.29 | 0.29 | 0.31 | |
Share Based Compensation of Revenue |
9.74% | 11.81% | 15.78% | 13.62% | |
Graham Net Nets |
0.06 | 0.15 | 0.18 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.58%) | (17.55%) | (27.07%) | (41.03%) | |
Free Cash Flow Yield |
(3.24%) | (15.83%) | (20.76%) | (34.47%) | |
Revenue per Share |
0.00 | 0.22 | 0.17 | 0.24 | |
Operating CF per Share |
0.00 | (0.14) | (0.17) | (0.15) | |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.03) | |
Free Cash Flow per Share |
0.00 | (0.15) | (0.19) | (0.17) | |
Cash per Share |
— | 0.66 | 0.75 | 0.83 | |
Shareholders Equity per Share |
0.00 | 1.64 | 1.72 | 1.95 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 1.64 | 1.72 | 1.95 | |
Free Cash Flow |
(9.21) | (66.28) | (78.68) | (61.88) | |
Working Capital |
443.86 | 357.41 | 337.08 | 304.33 | |
Capital Expenditures |
(4.74) | (5.44) | (6.61) | (9.32) | |
Net Current Asset Value |
371.08 | 284.77 | 262.59 | 228.10 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.09 | 0.11 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
86.87 | 81.03 | 76.35 | 75.89 | |
Average Payables |
26.44 | 29.11 | 32.97 | 24.83 | |
Average Inventory |
53.47 | 52.71 | 61.96 | 51.60 | |
Average Assets |
948.08 | 911.48 | 946.20 | 911.80 | |
Average Common Equity |
757.47 | 717.26 | 744.81 | 704.49 |
Columns are period end dates · fundamentals updated 5 Nov 2026